Filter
Period
Filter by
recent search
Showing: 1 – 05 of 153 Regulated Information
30 June 2023
30 June 2023
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
PARIS, FRANCE, 30 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual…
29 June 2023
29 June 2023
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 29 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted in favor of investigational palovarotene as an effective treatment, with a…
27 June 2023
27 June 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2023
Aggregated presentation by day and by market
20 June 2023
20 June 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023
Aggregated presentation by day and by market
19 June 2023
19 June 2023